Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
HIV Breakthrough as New Injection 89% More Effective Than PrEP
"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less information about how effective PrEP pills are among people who inject drugs, we know that PrEP pills reduce the risk of getting HIV by at least 74 percent when taken as prescribed," the CDC says.
New HIV prevention injection offers 96% protection
For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including attending doctor's visits every three months and – most importantly – consistency.
Twice-Yearly Injection 96% Effective in Preventing HIV Infection
A twice-yearly injection of Sunlenca (lenacapavir) reduces the risk of HIV infection by 96%, which is significantly more effective than oral pre-exposure prophylaxis (PrEP) using pills like Truvada, researchers report in the New England Journal of Medicine.
HIV infections can be prevented – why some people act to protect themselves, and others don’t
People are at the heart of the HIV pandemic, so it’s important to understand how they make protection decisions.
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure prophylaxis (PrEP) against once-daily oral Truvada.
Twice-Yearly Injection Reduces Risk of HIV Infection by 96%
For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including attending doctor's visits every three months and—most importantly—cons
'Huge relief' as new drug found to effectively prevent HIV infection
A vaccination with the drug lenacapavir offers an effective protection against a HIV infection, according to newly published research from the pivotal phase-three study "Purpose 2". The option to vaccinate against HIV only every six months is a genuine breakthrough,
Opinion
The New Republic on MSN
15h
Opinion
Big Pharma Is the Only Reason Anyone Still Dies From HIV
While antiviral drugs to treat HIV had been approved a decade earlier, only five out of 33 million people who carried the ...
15h
on MSN
HIV prevention pills should be free, but insurers are still charging
Insurance companies have to pay for PrEP under federal rules, but some skirt the requirement for free access to the treatment ...
11h
on MSN
Why is a cure for HIV so elusive?
Schulich School of Medicine & Dentistry researchers are on the cutting-edge of the study of HIV, working toward treatments ...
3d
Fewest New HIV Cases Since Late 1980s: UNAIDS Report
Fewer people contracted HIV last year than at any point since the rise of the disease in the late 1980s, the United Nations ...
6h
Gilead's Twice-Yearly Lenacapavir Reduces HIV Infection Risk
According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...
The Kenya Times on MSN
2d
Bill Gates Opens Up on Finding Lifetime HIV Vaccine
U.S. philanthropist and entrepreneur Bill Gates has opened up about the search for a lifetime HIV vaccine, rather than one ...
2d
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results ...
Medscape
4d
Family Doctors Can Intervene to Treat and Prevent STIs
Many family physicians may be unaware of doxy PEP as a means of avoiding STIs. “Doxy PEP is an incredible tool that can be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
HIV
Gilead Sciences
Feedback